Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease

Partow Kebriaei, Luis Isola, Erkut Bahceci, Kent Holland, Scott Rowley, Joseph McGuirk, Marcel P DeVetten, Jan Jansen, Roger Herzig, Michael Schuster, Rod Monroy, Joseph Uberti

Research output: Contribution to journalArticle

269 Citations (Scopus)

Abstract

The unique immunomodulatory properties of mesenchymal stem cells (MSCs) make them a rationale agent to investigate for graft-versus-host disease (GVHD). Human MSCs were used to treat de novo acute GVHD (aGVHD). Patients with grades II-IV GVHD were randomized to receive 2 treatments of human MSCs (Prochymal®) at a dose of either 2 or 8 million MSCs/kg in combination with corticosteroids. Patients received GVHD prophylaxis with tacrolimus, cyclosporine, (CsA) or mycophenolate mofetil (MMF). Study endpoints included safety of Prochymal administration, induction of response to Prochymal, and overall response of aGVHD by day 28, and long-term safety. Thirty-two patients were enrolled, with 31 evaluable: 21 males, 10 females; median age 52 years (range: 34-67). Twenty-one patients had grade II, 8 had grade III, and 3 had grade IV aGVHD. Ninety-four percent of patients had an initial response to Prochymal (77% complete response [CR] and 16% partial response [PR]). No infusional toxicities or ectopic tissue formations were reported. There was no difference with respect to safety or efficacy between the low and high Prochymal dose. In conclusion, Prochymal can be infused safely into patients with aGVHD and induces response in a high proportion of GVHD patients.

Original languageEnglish (US)
Pages (from-to)804-811
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume15
Issue number7
DOIs
StatePublished - Jul 1 2009

Fingerprint

Graft vs Host Disease
Mesenchymal Stromal Cells
Adrenal Cortex Hormones
Safety
Therapeutics
Mycophenolic Acid
Choristoma
Tacrolimus
Cyclosporine

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Graft-versus-host disease
  • Mesenchymal stem cells

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease. / Kebriaei, Partow; Isola, Luis; Bahceci, Erkut; Holland, Kent; Rowley, Scott; McGuirk, Joseph; DeVetten, Marcel P; Jansen, Jan; Herzig, Roger; Schuster, Michael; Monroy, Rod; Uberti, Joseph.

In: Biology of Blood and Marrow Transplantation, Vol. 15, No. 7, 01.07.2009, p. 804-811.

Research output: Contribution to journalArticle

Kebriaei, P, Isola, L, Bahceci, E, Holland, K, Rowley, S, McGuirk, J, DeVetten, MP, Jansen, J, Herzig, R, Schuster, M, Monroy, R & Uberti, J 2009, 'Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease', Biology of Blood and Marrow Transplantation, vol. 15, no. 7, pp. 804-811. https://doi.org/10.1016/j.bbmt.2008.03.012
Kebriaei, Partow ; Isola, Luis ; Bahceci, Erkut ; Holland, Kent ; Rowley, Scott ; McGuirk, Joseph ; DeVetten, Marcel P ; Jansen, Jan ; Herzig, Roger ; Schuster, Michael ; Monroy, Rod ; Uberti, Joseph. / Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease. In: Biology of Blood and Marrow Transplantation. 2009 ; Vol. 15, No. 7. pp. 804-811.
@article{f5b8ce03f00344279b5f5fd7806b6efd,
title = "Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease",
abstract = "The unique immunomodulatory properties of mesenchymal stem cells (MSCs) make them a rationale agent to investigate for graft-versus-host disease (GVHD). Human MSCs were used to treat de novo acute GVHD (aGVHD). Patients with grades II-IV GVHD were randomized to receive 2 treatments of human MSCs (Prochymal{\circledR}) at a dose of either 2 or 8 million MSCs/kg in combination with corticosteroids. Patients received GVHD prophylaxis with tacrolimus, cyclosporine, (CsA) or mycophenolate mofetil (MMF). Study endpoints included safety of Prochymal administration, induction of response to Prochymal, and overall response of aGVHD by day 28, and long-term safety. Thirty-two patients were enrolled, with 31 evaluable: 21 males, 10 females; median age 52 years (range: 34-67). Twenty-one patients had grade II, 8 had grade III, and 3 had grade IV aGVHD. Ninety-four percent of patients had an initial response to Prochymal (77{\%} complete response [CR] and 16{\%} partial response [PR]). No infusional toxicities or ectopic tissue formations were reported. There was no difference with respect to safety or efficacy between the low and high Prochymal dose. In conclusion, Prochymal can be infused safely into patients with aGVHD and induces response in a high proportion of GVHD patients.",
keywords = "Allogeneic hematopoietic stem cell transplantation, Graft-versus-host disease, Mesenchymal stem cells",
author = "Partow Kebriaei and Luis Isola and Erkut Bahceci and Kent Holland and Scott Rowley and Joseph McGuirk and DeVetten, {Marcel P} and Jan Jansen and Roger Herzig and Michael Schuster and Rod Monroy and Joseph Uberti",
year = "2009",
month = "7",
day = "1",
doi = "10.1016/j.bbmt.2008.03.012",
language = "English (US)",
volume = "15",
pages = "804--811",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease

AU - Kebriaei, Partow

AU - Isola, Luis

AU - Bahceci, Erkut

AU - Holland, Kent

AU - Rowley, Scott

AU - McGuirk, Joseph

AU - DeVetten, Marcel P

AU - Jansen, Jan

AU - Herzig, Roger

AU - Schuster, Michael

AU - Monroy, Rod

AU - Uberti, Joseph

PY - 2009/7/1

Y1 - 2009/7/1

N2 - The unique immunomodulatory properties of mesenchymal stem cells (MSCs) make them a rationale agent to investigate for graft-versus-host disease (GVHD). Human MSCs were used to treat de novo acute GVHD (aGVHD). Patients with grades II-IV GVHD were randomized to receive 2 treatments of human MSCs (Prochymal®) at a dose of either 2 or 8 million MSCs/kg in combination with corticosteroids. Patients received GVHD prophylaxis with tacrolimus, cyclosporine, (CsA) or mycophenolate mofetil (MMF). Study endpoints included safety of Prochymal administration, induction of response to Prochymal, and overall response of aGVHD by day 28, and long-term safety. Thirty-two patients were enrolled, with 31 evaluable: 21 males, 10 females; median age 52 years (range: 34-67). Twenty-one patients had grade II, 8 had grade III, and 3 had grade IV aGVHD. Ninety-four percent of patients had an initial response to Prochymal (77% complete response [CR] and 16% partial response [PR]). No infusional toxicities or ectopic tissue formations were reported. There was no difference with respect to safety or efficacy between the low and high Prochymal dose. In conclusion, Prochymal can be infused safely into patients with aGVHD and induces response in a high proportion of GVHD patients.

AB - The unique immunomodulatory properties of mesenchymal stem cells (MSCs) make them a rationale agent to investigate for graft-versus-host disease (GVHD). Human MSCs were used to treat de novo acute GVHD (aGVHD). Patients with grades II-IV GVHD were randomized to receive 2 treatments of human MSCs (Prochymal®) at a dose of either 2 or 8 million MSCs/kg in combination with corticosteroids. Patients received GVHD prophylaxis with tacrolimus, cyclosporine, (CsA) or mycophenolate mofetil (MMF). Study endpoints included safety of Prochymal administration, induction of response to Prochymal, and overall response of aGVHD by day 28, and long-term safety. Thirty-two patients were enrolled, with 31 evaluable: 21 males, 10 females; median age 52 years (range: 34-67). Twenty-one patients had grade II, 8 had grade III, and 3 had grade IV aGVHD. Ninety-four percent of patients had an initial response to Prochymal (77% complete response [CR] and 16% partial response [PR]). No infusional toxicities or ectopic tissue formations were reported. There was no difference with respect to safety or efficacy between the low and high Prochymal dose. In conclusion, Prochymal can be infused safely into patients with aGVHD and induces response in a high proportion of GVHD patients.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Graft-versus-host disease

KW - Mesenchymal stem cells

UR - http://www.scopus.com/inward/record.url?scp=67149093649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67149093649&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2008.03.012

DO - 10.1016/j.bbmt.2008.03.012

M3 - Article

VL - 15

SP - 804

EP - 811

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 7

ER -